TY - JOUR
T1 - Risk of Treatment Failure and Death after Ablation in Hepatocellular Carcinoma Patients—
T2 - A Multiparametric Prediction
AU - Muñoz-Martínez, Sergio
AU - Sapena, Victor
AU - García-Criado, Ángeles
AU - Darnell, Anna
AU - Forner, Alejandro
AU - Belmonte, Ernest
AU - Sanduzzi-Zamparelli, Marco
AU - Rimola, Jordi
AU - Soler, Alexandre
AU - Llarch, Neus
AU - Iserte, Gemma
AU - Mauro, Ezequiel
AU - Ayuso, Carmen
AU - Rios, Jose
AU - Bruix, Jordi
AU - Vilana, Ramon
AU - Reig, María
N1 - Publisher Copyright:
© 2023 by the authors.
PY - 2023/6/21
Y1 - 2023/6/21
N2 - Background: Ablation is a first-line treatment for Barcelona Clinic Liver Cancer (BCLC)-0/A hepatocellular carcinoma (HCC). However, there are scarce data about patients’ outcomes after recurrence. The present study evaluates the impact of patient and tumor characteristics at baseline and at recurrence on the Clinical Decision-Making process. Methods: We evaluated BCLC-0/A patients treated with percutaneous ablation from January 2010 to November 2018. Clinical and radiological data such as age, tumor location at ablation, pattern of recurrence/progression, and comorbidities during follow-up were registered. Tumor location was divided into ‘suboptimal’ vs. ‘optimal’ locations for ablation. The Clinical Decision-Making was based on tumor burden, liver dysfunction, or comorbidities. The statistical analysis included the time-to-recurrence/progression, censoring at time of death, date of last follow-up or liver transplantation, and time-to-event was estimated by the Kaplan–Meier method and Cox regression models to evaluate the risk of an event of death and change of treatment strategy. Results: A total of 225 patients [39.1% BCLC-0 and 60.9% BCLC-A] were included, 190 had unifocal HCC and 82.6% were ≤3 cm. The complete response rate and median overall survival were 96% and 60.7 months. The HCC nodules number (Hazard Ratio—HR 3.1), Child-Pugh (HR 2.4), and Albumin-Bilirubin score (HR 3.2) were associated with increased risk of death during follow-up. HCC in ‘suboptimal location’ presented a shorter time to recurrence. When comorbidities prevented further loco-regional or systemic treatment, the risk of death was significantly increased (HR 2.0, p = 0.0369) in comparison to those who received treatment. Conclusions: These results expose the impact of non-liver comorbidities when considering treatment for recurrence after ablation in the real-world setting and in research trials. Ultimately, we identified an orphan population for which effective interventions are needed.
AB - Background: Ablation is a first-line treatment for Barcelona Clinic Liver Cancer (BCLC)-0/A hepatocellular carcinoma (HCC). However, there are scarce data about patients’ outcomes after recurrence. The present study evaluates the impact of patient and tumor characteristics at baseline and at recurrence on the Clinical Decision-Making process. Methods: We evaluated BCLC-0/A patients treated with percutaneous ablation from January 2010 to November 2018. Clinical and radiological data such as age, tumor location at ablation, pattern of recurrence/progression, and comorbidities during follow-up were registered. Tumor location was divided into ‘suboptimal’ vs. ‘optimal’ locations for ablation. The Clinical Decision-Making was based on tumor burden, liver dysfunction, or comorbidities. The statistical analysis included the time-to-recurrence/progression, censoring at time of death, date of last follow-up or liver transplantation, and time-to-event was estimated by the Kaplan–Meier method and Cox regression models to evaluate the risk of an event of death and change of treatment strategy. Results: A total of 225 patients [39.1% BCLC-0 and 60.9% BCLC-A] were included, 190 had unifocal HCC and 82.6% were ≤3 cm. The complete response rate and median overall survival were 96% and 60.7 months. The HCC nodules number (Hazard Ratio—HR 3.1), Child-Pugh (HR 2.4), and Albumin-Bilirubin score (HR 3.2) were associated with increased risk of death during follow-up. HCC in ‘suboptimal location’ presented a shorter time to recurrence. When comorbidities prevented further loco-regional or systemic treatment, the risk of death was significantly increased (HR 2.0, p = 0.0369) in comparison to those who received treatment. Conclusions: These results expose the impact of non-liver comorbidities when considering treatment for recurrence after ablation in the real-world setting and in research trials. Ultimately, we identified an orphan population for which effective interventions are needed.
KW - Ablation
KW - Clinical decision-making
KW - Comorbidities
KW - Elderly
KW - Hepatocellular carcinoma
KW - Pattern of progression
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=85164975541&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/e4579f4c-6f26-3ead-bc24-620e8893d449/
U2 - 10.3390/cancers15133269
DO - 10.3390/cancers15133269
M3 - Article
C2 - 37444380
AN - SCOPUS:85164975541
SN - 2072-6694
VL - 15
SP - 3269
JO - Cancers
JF - Cancers
IS - 13
M1 - 3269
ER -